Corcept Therapeutics Incorporated focuses on the research and development of cortisol modulators, which are molecules that regulate cortisol activity at the glucocorticoid receptor. The company has discovered over 1,000 proprietary cortisol modulators and received FDA approval for Korlym® (mifepristone), the first treatment for hypercortisolism (Cushing syndrome). Corcept conducts more than 30 ongoing studies across various disease areas, including endocrinology, oncology, metabolism, and neurology, aiming to advance the treatment of serious diseases through cortisol modulation.
